Management of Thrombocytopenia in Patients with Bone Cancer

Initial Evaluation

The American Society of Hematology recommends excluding other causes of thrombocytopenia before attributing it to cancer or its treatment, such as heparin-induced thrombocytopenia, disseminated intravascular coagulation, infections, or drug reactions 1
The International Society on Thrombosis and Haemostasis suggests evaluating the risk of bleeding based on the type of cancer, current treatments, history of bleeding, associated coagulopathies, and comorbidities 2

For patients with a platelet count ≥ 50 x 10⁹/L, the American College of Chest Physicians recommends administering full-dose therapeutic anticoagulation without platelet transfusion 3
For patients with severe thrombocytopenia (< 50 x 10⁹/L) and cancer-associated thrombosis (CAT), the International Society on Thrombosis and Haemostasis suggests using full-dose anticoagulation (HBPM/HNF) with transfusion support to maintain a platelet count ≥ 40-50 x 10⁹/L 3, 4
For patients with CAT and a platelet count between 25-50 x 10⁹/L, the American Society of Hematology recommends reducing the dose of HBPM to 50% of the therapeutic dose or using a prophylactic dose 3, 4
For patients with a platelet count < 25 x 10⁹/L, the International Society on Thrombosis and Haemostasis suggests temporarily suspending anticoagulation 3

The European Society for Medical Oncology notes that patients with bone metastases may have significant bone marrow failure with anemia and thrombocytopenia, which is associated with a poor prognosis 2
The American Society of Clinical Oncology recommends careful monitoring of signs of bleeding, particularly in patients with a platelet count < 25 x 10⁹/L 3

The American Society of Hematology suggests that platelet transfusions are the first-line treatment for patients with a platelet count < 25 x 10⁹/L or active bleeding 2

The International Society on Thrombosis and Haemostasis warns against confusing cancer-related thrombocytopenia with other causes, such as immune thrombocytopenia secondary to lymphoproliferative neoplasms 2
The American College of Chest Physicians notes that the correlation between platelet counts between 10-50 x 10⁹/L and the risk of bleeding is not clearly established in the literature 2
The European Society for Medical Oncology recommends careful monitoring of signs of bleeding, particularly in patients with a platelet count < 25 x 10⁹/L, and suggests that HBPM remains the preferred anticoagulant in patients with cancer and thrombocytopenia 3, 5